Cathie Wood’s ARK Invest Buys Nearly 60,000 Shares of CRISPR
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday. Specifically, these exchange-traded funds bought roughly $4.6 million worth of CRISPR Therapeutics AG (NASDAQ: CRSP | CRSP Price Prediction), as the prices of these funds were down about 1% on Wednesday. Note that their performance is fairly negative in the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 14,400 shares of CRISPR, and ARK Innovation ETF (NYSEARCA: ARKK) scooped up 45,500 shares. At Wednesday’s closing price, this would have valued the sales at roughly $4.6 million altogether. Even though this is a small fraction of their total holdings, every little bit counts. The innovation ETF is down about 24% and the other is down closer to 36% in the past year.
Check out all the ARK Invest trades for Wednesday as well:
| Fund | Direction | Ticker | Name | Shares |
|---|---|---|---|---|
| ARKF | Buy | TDOC | TELADOC HEALTH | 10,000 |
| ARKG | Buy | TDOC | TELADOC HEALTH | 22,500 |
| ARKG | Buy | SGFY | SIGNIFY HEALTH | 105,770 |
| ARKG | Buy | PSNL | PERSONALIS | 33,753 |
| ARKG | Buy | MASS | 908 DEVICES | 56,909 |
| ARKG | Buy | CRSP | CRISPR THERAPEUTICS | 14,400 |
| ARKG | Buy | BLI | BERKELEY LIGHTS | 50,528 |
| ARKG | Buy | BEAM | BEAM THERAPEUTICS | 5,855 |
| ARKG | Sell | TXG | 10X GENOMICS | 33,989 |
| ARKG | Sell | VRTX | VERTEX PHARMACEUTICALS | 24,007 |
| ARKK | Buy | VCYT | VERACYTE | 38,715 |
| ARKK | Buy | TWOU | 2U | 107,448 |
| ARKK | Buy | TDOC | TELADOC HEALTH | 97,300 |
| ARKK | Buy | SSYS | STRATASYS | 249,771 |
| ARKK | Buy | NVTA | INVITAE | 51,355 |
| ARKK | Buy | CRSP | CRISPR THERAPEUTICS | 45,500 |
| ARKK | Sell | TSLA | TESLA | 22,816 |
| ARKQ | Buy | XPEV | XPENG | 43,100 |
| ARKQ | Buy | PATH | UIPATH | 31,830 |
| ARKQ | Buy | MTLS | MATERIALISE | 20,338 |
| ARKQ | Sell | TSLA | TESLA | 5,069 |
| ARKW | Buy | TDOC | TELADOC HEALTH | 17,000 |
| ARKX | Buy | BLDE | BLADE AIR MOBILITY | 28,372 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of 247wallst.com.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
